How is melanotan I dosed and mixed?
Every vial at a glance.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units |
| 10 mg | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units |
Strengths, mixing and syringe units
The table is arithmetic only: no regulator or label states a melanotan I vial strength, and the doses in it are worked examples, not doses from any source; the trials read gave melanotan I by body weight, from 0.08 to 0.21 mg/kg subcutaneously in Ugwu 1997.1 No label or regulator text says which water or how much for melanotan I powder; a 2017 review says the trial doses were given in saline injected subcutaneously, with no concentration stated,3 and a 2017 review of unregulated melanotans (Habbema 2017) notes questions about their preparation, administration and dosage.4 No melanotan I concentration is stated in any source read, so a syringe mark cannot be tied to a source; the mixing calculator and the mixing guide do the arithmetic from any strength.
Trial doses, arm by arm
The trials read set doses by body weight in mg/kg, and the journal summary of Levine 1991, a trial in twenty-eight healthy white men, gives no mg dose.5 No cycle length beyond the trial schedules in the table is sourced.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Ugwu 19971 | 0.08 to 0.21 mg/kg subcutaneously, and 0.16 mgkg-1 intravenously and by mouth, randomized crossover, over five consecutive days for 2 weeks (ten doses) | three male volunteers | 2 weeks |
| Levine 19915 | 10 subcutaneous injections of NDP-MSH or saline, randomized, placebo-controlled, double-blind; the journal summary gives no mg dose | Twenty-eight healthy white men | 12 days, 7 weeks follow-up |
| Dorr 20006 | 0.16 mg/kg/day subcutaneously, Monday to Friday, 10 injections | Seven volunteers (six males and one female) | two weeks |
| Dorr 20047 | 0.08 mg/kg per day subcutaneously against isotonic sodium chloride injections, then 0.16 mg/kg per day with UV-B, then sunlight plus 0.16 mg/kg 5 days per week against sunlight alone | 4 on MT-1 and 4 on saline, then 12, then 8 | 10 days, 10 days, 4 weeks |
| Barnetson 20068 | 0.16 mg/kg by subcutaneous injection into the abdomen, three 10-day cycles, against placebo | 65 completers | 3 months |
What labels and trials give for melanotan I
No label or approved dose exists for melanotan I itself in the DailyMed, EMA, TGA and FDA pages checked. The US label for Scenesse (afamelanotide) covers adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), and supplies it as a single 16 mg implant in a glass vial, not a powder for mixing.2 The EMA summary gives one implant under the skin every 2 months, before and during periods of high sunlight exposure, and says the number per year depends on how much protection from the sun is needed, with three a year recommended and a maximum of 4.9 The label places it subcutaneously above the anterior supra-iliac crest, given by a trained health care professional.2
Storage
The Scenesse label says to store the implant in a refrigerator at 2°C to 8°C, protected from light.2 No storage or stability data for melanotan I powder or a mixed solution is sourced.
Frequently asked questions
Does melanotan I work by mouth?
In Ugwu 1997 (three male volunteers), the subcutaneous dose was completely bioavailable compared to the intravenous dose, and oral dosing at 0.16 mgkg-1 gave no detectable drug levels;1 a 2017 review says neither oral nor transdermal application resulted in measurable plasma concentrations or pigmentation response.3
Who gives the Scenesse implant?
The EMA says Scenesse is only prescribed by specialist doctors in recognised centres for treating EPP, and is used only by doctors who have been properly trained.9
References
- Biopharmaceutics & drug disposition (PubMed abstract). Skin pigmentation and pharmacokinetics of melanotan-I in humans. 1997. pubmed.ncbi.nlm.nih.gov
- CLINUVEL INC. via DailyMed (US label). HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SCENESSE safely and effectively. See full prescribing information for SCENESSE. SCENESSE® (afamelanotide) implant, for subcutaneous use. Initial U.S. Approval: 2019. 2026. dailymed.nlm.nih.gov
- Clinical pharmacokinetics (PubMed abstract). Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. 2017. pubmed.ncbi.nlm.nih.gov
- International journal of dermatology (PubMed abstract). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. 2017. pubmed.ncbi.nlm.nih.gov
- JAMA (PubMed abstract). Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. 1991. pubmed.ncbi.nlm.nih.gov
- Photochemistry and photobiology (PubMed abstract). Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. 2000. pubmed.ncbi.nlm.nih.gov
- Archives of dermatology (PubMed abstract). Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. 2004. pubmed.ncbi.nlm.nih.gov
- The Journal of investigative dermatology (PubMed abstract). [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. 2006. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency. Scenesse | European Medicines Agency (EMA). ema.europa.eu